Evidence map›Paper›PMID 26577796›Full record

Trial reportDiabetologia2016

Effect of atorvastatin on glycaemia progression in patients with diabetes: an analysis from the Collaborative Atorvastatin in Diabetes Trial (CARDS).

Shona J Livingstone, Helen C Looker, Tahira Akbar, D John Betteridge, Paul N Durrington, Graham A Hitman, H Andrew W Neil, John H Fuller, Helen M Colhoun

Registry-linked trialOpen access · hybridAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Diabetologia, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It reports registered trial NCT04945122. Cited by 17 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 1 pooled it
5.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04945122 phase4unknown status

Comparison of Atorvastatin and Pitavastatin on the Effect of HbA1c in Acute Myocardial Infarction (AMI) Patients With Abnormal Glucose Metabolism: a Multicenter Prospective Randomized Clinical Trial

Ran2015Enrolled900Registered outcomes2Posted comparisons0ConditionsAcute Myocardial Infarction, Glucose Metabolism DisordersArmsAtorvastatin, Pitavastatin
PMID 21812889PMID 24998014PMID 25575403PMID 26084792PMID 22878405PMID 18981652PMID 23352266PMID 21028996PMID 27181110PMID 25109606PMID 25312577PMID 21693744other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Review
  7. Observational
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Simvastatin Rapidly and Reversibly Inhibits Insulin Secretion in Intact Single-Islet Cultures.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

Shona J LivingstoneDiabetes Epidemiology Unit, Division of Population Health Sciences, University of Dundee, The Mackenzie Building, Kirsty Semple Way, Dundee, DD2 4BF, Scotland, UK.
Helen C LookerDiabetes Epidemiology Unit, Division of Population Health Sciences, University of Dundee, The Mackenzie Building, Kirsty Semple Way, Dundee, DD2 4BF, Scotland, UK.
Tahira AkbarDiabetes Epidemiology Unit, Division of Population Health Sciences, University of Dundee, The Mackenzie Building, Kirsty Semple Way, Dundee, DD2 4BF, Scotland, UK.
D John BetteridgeDepartment of Endocrinology and Diabetes, University College Hospital, London, UK.
Paul N DurringtonCardiovascular Research Group, School of Biosciences, University of Manchester, Manchester, UK.
Graham A HitmanBlizard Institute, Barts and the London School of Medicine, Queen Mary University of London, London, UK.
H Andrew W NeilOxford Centre for Diabetes, Endocrinology and Metabolism, University of Oxford, Oxford, UK.
John H FullerDepartment of Epidemiology and Public Health, University College London, London, UK.
Helen M ColhounDiabetes Epidemiology Unit, Division of Population Health Sciences, University of Dundee, The Mackenzie Building, Kirsty Semple Way, Dundee, DD2 4BF, Scotland, UK. h.colhoun@dundee.ac.uk.
University of Dundee · GBUniversity College London · GBOxford Centre for Diabetes, Endocrinology and Metabolism · GBQueen Mary University of London · GBUniversity of Manchester · GB

Funding

Department of Health
6 · The paper itself

Abstract

aims/hypothesisIn an individual-level analysis we examined the effect of atorvastatin on glycaemia progression in type 2 diabetes and whether glycaemia effects reduce the prevention of cardiovascular disease (CVD) with atorvastatin.

methodsThe study population comprised 2,739 people taking part in the Collaborative Atorvastatin Diabetes Study (CARDS) who were randomised to receive atorvastatin 10 mg or placebo and who had post-randomisation HbA1c data. This secondary analysis used Cox regression to estimate the effect of atorvastatin on glycaemia progression, defined as an increase in HbA1c of ≥ 0.5% (5.5 mmol/mol) or intensification of diabetes therapy. Mixed models were used to estimate the effect of atorvastatin on HbA1c as a continuous endpoint.

resultsGlycaemia progression occurred in 73.6% of participants allocated placebo and 78.1% of those allocated atorvastatin (HR 1.18 [95% CI 1.08, 1.29], p < 0.001) by the end of follow-up. The HR was 1.22 (95% CI 1.19, 1.35) in men and 1.11 (95% CI 0.95, 1.29) in women (p = 0.098 for the sex interaction). A similar effect was seen in on-treatment analyses: HR 1.20 (95% CI 1.07, 1.35), p = 0.001. The net mean treatment effect on HbA1c was 0.14% (95% CI 0.08, 0.21) (1.5 mmol/mol). The effect did not increase through time. Diabetes treatment intensification alone did not differ with statin allocation. Neither baseline nor 1-year-attained HbA1c predicted subsequent CVD, and the atorvastatin effect on CVD did not vary by HbA1c change (interaction p value 0.229). CONCLUSIONS/

interpretationThe effect of atorvastatin 10 mg on glycaemia progression among those with diabetes is statistically significant but very small, is not significantly different between sexes, does not increase with duration of statin and does not have an impact on the magnitude of CVD risk reduction with atorvastatin.

Indexed as

AdultAgedAnticholesteremic AgentsAtorvastatinBlood GlucoseDiabetes Mellitus, Type 2Disease ProgressionFemaleGlycated HemoglobinHumansIrelandMaleMiddle AgedUnited KingdomAnticholesteremic AgentsAtorvastatinBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanAtorvastatinCardiovascular diseaseGlycaemiaHbA1c

Identifiers

PMID26577796
PMCPMC4705133
OpenAlexW2175477592

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.